Microbial modulation of CFTR modulator exposure: In vitro interactions between elexacaftor-tezacaftor-ivacaftor and pulmonary and gut bacteria from people with cystic fibrosis.
BACKGROUND Elexacaftor-tezacaftor-ivacaftor (ETI) has transformed cystic fibrosis (CF) care, but individual responses remain variable. Although longitudinal studies indicate that ETI reshapes lung and gut microbiota, the contribution of direct drug-microbe interactions remains unclear. We used an in vitro pharmacomicro...